Antibody Levels Against Mumps Virus in Children After Implementation of the Two-Dose MMR Vaccine Policy - Fujian

Zhifei Chen1,2, Rui Chen2, Ruihong Wu1,2

  • 1Fujian Provincial Key Laboratory of Zoonosis Research, Fujian Provincial Center for Disease Control and Prevention, Fuzhou City, Fujian Province, China.

China CDC Weekly
|October 31, 2025
PubMed
Abstract

Insights

The two-dose Measles-Mumps-Rubella (MMR) vaccine policy improved immunity in young children in Fujian Province. However, waning immunity in adolescents necessitates ongoing surveillance for potential booster vaccinations.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The Measles-Mumps-Rubella (MMR) vaccine is vital for mumps prevention.
  • Baseline mumps virus antibody seroprevalence and geometric mean concentrations (GMCs) data existed before the two-dose policy in Fujian Province.

Purpose of the Study:

  • To evaluate the effectiveness of Fujian's two-dose MMR policy implemented in June 2020.
  • To assess mumps virus antibody seroprevalence and GMCs post-policy implementation.

Main Methods:

  • A 2023 serological survey was conducted in Fujian Province.
  • Data analysis compared post-policy results with pre-policy baseline data from 2018.

Main Results:

  • Overall seroprevalence was 79.53% with a GMC of 265.61 U/mL in 2023.
  • Significant immunity improvements were seen in children under 2 years.
  • A decline in antibody levels was observed in adolescents aged 15-17 years.
  • Two MMR doses provided higher immunity than one dose within 270 days.

Conclusions:

  • The two-dose MMR policy effectively enhanced early childhood immunity.
  • Waning immunity in adolescents highlights the need for continued serological surveillance.
  • Recommendations for booster vaccinations may be needed for individuals aged 6-19 years.